biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by rustycaton Nov 01, 2017 11:47am

67 Views

Post# 26888148

RE:RE:RE:Transend/ JUNO?? DIFFERENT TRANSEND?

Thanks, and I'll take your word on it. My questioning came from my search "juno bioasis" that brought up:
"bciq.biocentury.com/products/transcend

Juno Therapeutics Inc. (NASDAQ:JUNO) reported data from 54 evaluable ... The initial focus will be on advancing biOasis' Transcend peptide carrier, MTfp, ..."

Obviously faulty search parameters.....

Bullboard Posts

Investing with insurance and protection